Pharmacologic and Nonpharmacologic Therapeutic Approaches of Atrial Fibrillation in Patients With Congestive Heart Failure by Efremidis, Michalis & Pappas, Loukas
PHARMACOLOGIC AND NONPHARMACOLOGIC THERAPEUTIC APPROACHES OF AF IN PATIENTS WITH CHF
137
Pharmacologic and Nonpharmacologic 
Therapeutic Approaches of Atrial 
Fibrillation in Patients With Congestive 
Heart Failure
Michalis Efremidis, MD, Loukas Pappas, MD
A B S T R A C T
Atrial fibrillation (AF) and congestive heart failure (CHF) constitute the two “epi-
demics” of cardiovascular disease that often coexist and result in significant morbidity 
and mortality. Due to the complex interaction between AF and CHF, neither can be 
treated optimally without treating both. Despite an extensive amount of research and 
literature about each of these disorders separately, there is a paucity of controlled 
clinical trial data for the management of AF among patients with CHF. Conse-
quently, the optimal therapy of these patients remains controversial. New treatment 
approaches, both pharmacologic and nonpharmacologic, including catheter ablation 
techniques, as well as the results of ongoing clinical trials are likely to alter future AF 
management in CHF patients. 
Atrial fibrillation (AF) and congestive heart failure (CHF) are the two “epidemics” 
of cardiovascular disease that often coexist and result in considerable morbidity and 
mortality. A causal reciprocal relation exists between AF and CHF. The prevalence 
of AF has been observed to increase in proportion to the severity of CHF [1].
The objectives of AF treatment include rate control, cardioversion and main-
tenance of sinus rhythm, and prevention of thromboembolism. In patients with re-
cent-onset AF, anticoagulation and rate control should be used as front-line therapy 
before cardioversion is considered. If the patient is hemodynamically unstable, urgent 
cardioversion is clinically mandatory. For both acute and chronic AF it is clear that 
effective treatment of the arrhythmia depends on optimal management of CHF. It is 
essential not to overlook the treatment of precipitating factors and of the underlying 
etiology. A decrease in filling pressures and reduction of neuroendocrine activation 
will enhance spontaneous conversion to sinus rhythm in acute AF and help reduce 
ventricular rate in both acute and chronic AF. On the other hand, effective treatment of 
CHF may not be possible until ventricular rate is controlled or sinus rhythm restored. 
Angiotensin-converting enzyme inhibition and AT1 receptor blockade may prevent or 
delay the development of AF in patients with CHF by unloading the left atrium and 
inhibiting atrial fibrosis [2-9]. Anticoagulation with warfarin is imperative in patients 
with AF and CHF, even if sinus rhythm is maintained.
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R H Y T H M  V E R S U S  R A T E  C O N T R O L
The issue of rhythm control versus rate control for long-
term therapy of AF in CHF represents a challenging thera-
peutic dilemma and an object of intense debate. A subgroup 
analysis of the AFFIRM trial [10] showed a trend toward 
better survival associated with rhythm control among patients 
with CHF. However, AFFIRM was not adequately designed 
to assess treatment strategies in this subset of patients because 
only 23% of patients in this study had a history of CHF. A 
recent retrospective analysis [11] showed that there was no 
difference in mortality after 2 years of rate control or rhythm 
control treatments in patients with CHF in predominantly 
New York Heart Association (NYHA) functional classes III 
and IV. A recently published prespecified substudy of the 
RACE trial [12] demonstrated that in patients with mild to 
moderate CHF (NYHA II and III), cardiovascular morbidity 
and mortality were comparable between those treated with 
rate control and those treated with rhythm control. However, 
there was a trend for higher mortality and major bleeding in 
the rate control group. The primary objective of the ongoing 
AF-CHF trial [13] is to determine whether restoring and 
maintaining sinus rhythm significantly reduces cardiovascu-
lar mortality compared to a rate control strategy in patients 
with AF and CHF.
R H Y T H M  C O N T R O L  ( R E S T O R A T I O N  A N D  
M A I N T E N A N C E  O F  S I N U S  R H Y T H M )
Because of the high risk of proarrhythmia and the danger 
of exacerbating heart failure of class I antiarrhythmic drugs 
[14,15], IV ibutilide, IV or oral amiodarone, oral dofetilide, 
or direct current cardioversion are the preferred approaches 
to convert AF in patients with CHF. Although ibutilide is he-
modynamically well tolerated in patients with left ventricular 
(LV) dysfunction [16], the incidence of torsade de pointes 
(TdP) is increased in patients with a LV ejection fraction 
(LVEF) of <35% and therefore should be used with caution 
in this setting. The recurrence rate of AF after cardioversion 
in CHF is high. Prevention of AF with antiarrhythmic drugs is 
suboptimal. Oral amiodarone [17] or dofetilide [18,19] are the 
drugs of choice for maintenance of sinus rhythm. The use of 
amiodarone in patients with CHF and AF is not without risk. 
This population is very prone to the development of bradyar-
rhythmias requiring pacemaker implantation [20]. Amioda-
rone may increase the risk of sudden death in CHF patients 
with a history of previous TdP [21]. The rate of discontinua-
tion due to noncardiac adverse effects is high. Additionally, 
amiodarone increases the plasma levels of warfarin.
R A T E  C O N T R O L
Current ACC/AHA/ESC guidelines [22] consider the 
ventricular rate controlled when the ventricular response 
ranges between 60 and 80 bpm at rest and between 90 and 
115 bpm during moderate exercise. However, no study has 
validated these criteria. Rate control in AF is mainly based 
on pharmacological depression of atrioventricular (AV) nodal 
conduction.
There are no data on the safety and efficacy of â-blockers 
in acute AF and CHF. Esmolol, an intravenous, ultra-short 
acting â-blocker, may be a useful therapeutic option in the 
acute clinical setting due to its ability to be titrated according 
to changing circumstances. Moreover, despite the fact that â-
blocker therapy is considered the standard of care in chronic 
heart failure, it is uncertain whether â-blockade provides a 
similar degree of clinical benefit for CHF patients with AF. 
A retrospective analysis, which assessed the use of metoprolol 
or carvedilol in patients with CHF and sinus rhythm or AF, 
demonstrated a significant improvement in LVEF in both 
groups [23]. A retrospective analysis of the US Carvedilol 
Heart Failure Trials Project showed a significant improve-
ment in LVEF and a trend towards reduced mortality and 
CHF hospitalization [24]. Bisoprolol failed to show a survival 
benefit in patients with AF in a retrospective analysis of CIBIS 
II [25]. Prospective trials to clarify the impact of â-blocker 
therapy and the optimal therapeutic strategy in this group of 
patients are warranted.
In acute AF, digoxin is relatively slow and ineffective in 
controlling heart rate. Digoxin may also be ineffective in 
controlling heart rate in chronic AF when sympathetic tone 
is increased, as occurs in worsening CHF and during exer-
cise [26-28]. However, in the context of chronic heart failure, 
digoxin may improve symptoms and reduce hospitalization 
[29,30]. Additionally, digoxin and â-blockers produce a syn-
ergistic effect on the AV node [31]. A retrospective analysis of 
the US Carvedilol Heart Failure Trials Project demonstrated 
a better survival benefit of carvedilol in patients with CHF 
treated with digoxin [24]. In a group of 47 patients with pre-
dominantly NYHA II CHF, the combination of carvedilol and 
digoxin was superior to either carvedilol or digoxin alone in 
controlling ventricular rate and reducing symptoms [33].
Amiodarone is an interesting alternative in patients in 
whom both rapid rate control and cardioversion are considered 
appropiate [33]. Verapamil and diltiazem should be avoided 
in the acute setting as they may worsen CHF. For long-term 
rate control of chronic AF, diltiazem is a controversial alter-
native [34-36].
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N O N P H A R M A C O L O G I C  T H E R A P Y
In 10% to 15% of patients with AF ventricular rate cannot 
be controlled sufficiently by pharmacologic means [37]. In 
such cases, radiofrequency catheter ablation of the AV node 
with permanent pacemaker implantation (“ablate and pace” 
strategy) is a useful alternative. The only randomized con-
trolled study comparing pharmacological rate control versus 
AV node ablation and VVIR pacing in AF patients with CHF 
demonstrated an improvement in symptoms in the “ablate and 
pace” group [38]. The choice of pacing site appears crucial in 
the setting of CHF. The PAVE trial [39] prospectively com-
pared chronic biventricular pacing to right ventricular pacing 
in patients undergoing ablation of the AV node for manage-
ment of AF with rapid ventricular rates and demonstrated that 
biventricular pacing provides a significant improvement in the 
6-min walk test and in LVEF compared to right ventricular 
pacing. These beneficial effects of cardiac resynchronization 
appear to be greater in patients with impaired systolic function 
or with symptomatic heart failure.
Limited available evidence suggests a beneficial effect 
of cardiac resynchronization therapy (CRT) in patients with 
chronic AF, although larger studies are needed. Several single-
center studies with a relatively small number of patients have 
demonstrated acute hemodynamic improvement in patients 
with chronic AF receiving CRT [40,41], as well as improvement 
in echocardiographic parameters [42]. Two studies reported 
comparable benefit of CRT in patients with AF as compared 
to patients with sinus rhythm [43,44]. To date, only one pro-
spective randomized and controlled trial designed to assess 
the efficacy of CRT in AF patients with severe CHF has been 
published [45]. It showed a significant improvement in NYHA 
functional class, 6-min walking distance and quality of life 
with effective CRT therapy (>85% of time). In addition, LV 
reverse remodeling was observed with a reduction in hospi-
talization rate for CHF. It was subsequently demonstrated 
that the benefit of CRT was sustained at 12 months [46]. An 
important issue remains whether CRT in patients with chronic 
AF should be accompanied by AV nodal ablation in order 
to avoid inhibition of resynchronization therapy by the rapid 
intrinsic AV nodal conduction. 
Curative catheter ablation for atrial fibrillation, currently 
effected with pulmonary vein isolation procedures, has been 
established as an effective therapeutic option mainly for pa-
tients without significant heart disease. A recent retrospective 
study examined the effect of catheter ablation of AF on LV 
function in 94 patients with LV dysfunction [47]. The study 
showed a nonsignificant overall increase of 5% in LVEF after 
ablation. However, a recently published study [48], which pro-
spectively evaluated the effect of catheter ablation for AF on 
LV function in patients with CHF, showed that restoration and 
maintenance of sinus rhythm by catheter ablation without the 
use of drugs significantly improve cardiac function, symptoms, 
exercise capacity, and quality of life.
C O N C L U S I O N  
Because of the complex interaction between AF and CHF, 
neither can be treated optimally without treating both. Despite 
the extensive amount of research and literature about each 
of these disorders separately, there is a paucity of controlled 
clinical trial data for the management of AF among patients 
with CHF. Consequently, the optimal therapy of these pa-
tients remains controversial. New treatment approaches, both 
pharmacologic and nonpharmacologic, as well as the results 
of ongoing clinical trials are likely to alter AF management 
in CHF patients in the near future.
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